|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-2-20
|
|
pubmed:abstractText |
High-risk neuroblastoma is characterized by poor survival rates, and the development of improved therapeutic approaches is a priority. Temozolomide and topotecan show promising clinical activity against neuroblastoma. Poly(ADP-ribose) polymerase-1 (PARP-1) promotes DNA repair and cell survival following genotoxic insult; we postulated that its inhibition may enhance the efficacy of these DNA-damaging drugs in pediatric cancers.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BoddyAlan VAV,
pubmed-author:CastelbuonoDeborah JDJ,
pubmed-author:CliffordSteven CSC,
pubmed-author:CurtinNicola JNJ,
pubmed-author:DanielRachel ARA,
pubmed-author:DrewYvetteY,
pubmed-author:HostomskyZdenekZ,
pubmed-author:MulliganEvan AEA,
pubmed-author:PlummerE RuthER,
pubmed-author:RozanskaAgata LAL,
pubmed-author:ThomasHuw DHD,
pubmed-author:TweddleDeborah ADA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1241-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19174487-Animals,
pubmed-meshheading:19174487-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19174487-Cell Line, Tumor,
pubmed-meshheading:19174487-Cell Proliferation,
pubmed-meshheading:19174487-Dacarbazine,
pubmed-meshheading:19174487-Drug Synergism,
pubmed-meshheading:19174487-Enzyme Inhibitors,
pubmed-meshheading:19174487-Humans,
pubmed-meshheading:19174487-Indoles,
pubmed-meshheading:19174487-Mice,
pubmed-meshheading:19174487-Neuroblastoma,
pubmed-meshheading:19174487-Poly(ADP-ribose) Polymerases,
pubmed-meshheading:19174487-Topotecan,
pubmed-meshheading:19174487-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
|
|
pubmed:affiliation |
Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
